Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

DiabetologiaJun 6, 2026
Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial

Clinical Context

We think this has broad domain relevance to RECIST 1.1.

WHO NewsJun 5, 2026
Africa CDC and WHO launch joint continental Ebola response plan

Clinical Context

We think this has broad domain relevance to RECIST 1.1.

WHO NewsMay 31, 2026
Joint statement by the Government of the Democratic Republic of the Congo and WHO concerning the outbreak of Ebola disease caused by the Bundibugyo virus

Clinical Context

We think this has broad domain relevance to RECIST 1.1.

RECIST 1.1

RECIST v1.1Standard Response Criteria for Solid Tumors

Radiographic Category

Scoring Definition

  • CR: Disappearance of all target and non-target lesions.
  • PR: ≥ 30% decrease in sum of diameters of target lesions.
  • PD: ≥ 20% increase in sum of diameters, or new lesions.
  • SD: Neither PR nor PD criteria met.

Response Outlook

SD

Clinical Strategy

Stable Disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Used across almost all solid tumor Phase II and III clinical trials.
Dictates the primary endpoints of Objective Response Rate (ORR) and Progression-Free Survival (PFS).
Used in routine practice to definitively rule whether a patient should continue their current cytotoxic or targeted therapy.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the iRECIST, PERCIST 2.0 or the mRECIST (HCC) to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

iRECIST
PERCIST 2.0
mRECIST
FIGO 2023
Oncotype DX Recurrence
TNM 8th
SAVER Score
Calvert Formula
PD-L1 TPS Interpretation
RANO 2.0
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.